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Objectives: to identify risk factors for infrainguinal bypass occlusion and quantify the predictive value of data available
before and after surgery.
Design: prospective study of 2650 patients who participated in a randomised trial of oral anticoagulants or aspirin after
infrainguinal bypass surgery.
Materials and methods: risk factors were determined by univariate Cox regression analysis, and entered in multivariate
analyses which distinguished two models: analysis of factors available from history and clinical examination, completed
by radiological and surgical data in the second model. To compare the information content of the two models,
receiver–operator characteristic (ROC) curves were computed.
Results: in all patients female gender, critical ischaemia, femorocrural bypass grafting and non-venous graft material
were independent risk factors. In patients with femoropopliteal bypasses female gender, critical ischaemia, poor run-off
and non-venous graft material, the latter even in patients with supragenicular bypasses, were independent risk factors.
The only significant risk factor in patients with femorocrural bypass grafts was use of a non-venous graft.
The information contained in the first model was poor, whereas the second model had a higher predictive value.
Conclusions: the major risk factor, even in above-knee bypasses, is non-venous graft material. The venous bypass graft
should be offered to patients whenever possible.
Key Words: Infrainguinal bypass; Peripheral bypass surgery; Femoropopliteal bypass; Femorocrural bypass; Graft occlusion;
Risk factors; Graft material; Multivariate analysis.
Introduction The aim of this study, therefore, was to identify
risk factors for graft occlusion and to quantify the
In patients not treated with antithrombotics post- predictive value of data available before and after
surgery in a large cohort of patients who were recruitedoperatively, 28–45% of all bypass grafts will occlude
in the first year after operation, most of them in an into a multicentre randomised trial of oral anti-
coagulants and aspirin after infrainguinal bypass graft-early stage.1–4 Failure of infrainguinal bypass grafts
remains, despite expert surgeons and meticulous sur- ing.
gical technique, a matter of concern for both patient
and surgeon. Based on patient history, symptoms,
pathological and anatomical findings and technical
aspects of surgery, we endeavour to assess the prob- Materials and Methods
ability of successful bypass surgery for each patient.
Few prospective studies have addressed the iden- Patients and baseline characteristics
tification of specific vascular risk factors for infra-
inguinal graft occlusion.5–7 Evidently, little is known All patients studied were included in the Dutch BOA
Study (Bypass, Oral anticoagulants or Aspirin Study),about the predictive value of variables generally con-
sidered as risk factors for graft occlusion. a multicentre randomised trial to compare the ef-
fectiveness of oral anticoagulants with that of aspirin
in preventing occlusions of bypass grafts and other
∗ Participating investigators are listed in the Appendix. thrombotic events. Background, design and results of† Please address all correspondence to: M. J. D. Tangelder, BOA
Trial Office, Bolognalaan 30, 3584 CJ Utrecht, The Netherlands. the trial have been reported elsewhere.8 The study was
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approved by the Ethics Committees of all participating The aim of the multivariate analysis was to find
independent predictors of graft occlusion. Variableshospitals and by the Dutch Health Insurance Council.
All patients who were enrolled in the study gave with a significant predictive value (95% CI does not
include 1) in the univariate analysis were sequentiallywritten informed consent. Between April 1995 and
March 1998, a total of 2650 patients were randomised. entered in the multivariate analysis by a stepwise
forward conditional approach. The default probabilityDemographic factors (age and gender), medical history
(angina pectoris, myocardial infarction, transient isch- value for inclusion of possible independent risk factors
in the model was 0.05. Factors were removed fromaemic attack (TIA) or stroke, and vascular inter-
vention), vascular risk factors (current smoking, the model if the probability value exceeded 0.10. The
multivariate analysis distinguished two models. Inhypertension, diabetes mellitus and hyperlipidaemia),
indication for surgery (intermittent claudication or the first model (the ‘‘office only’’ model), variables
available from patient history and clinical examinationcritical ischaemia, i.e. rest pain or tissue loss), brachial
and ankle blood pressures, arterial run-off (Ζone ver- only were analysed. In the second ‘‘complete’’ model
these factors were completed by data from radiologysus two or three arteries), site of distal anastomosis
(popliteal artery above or below knee versus crural or and surgery.
To compare the information content of the twopedal artery), graft material used (autologous vein or
non-venous, i.e. prosthetic, homogenous or composite models, receiver–operator characteristic (ROC) curves
were computed. The more an ROC curve is located ingraft material), and postoperative antithrombotic med-
ication were all recorded at baseline. Vascular inter- the upper left corner of the graph, the higher the
information content of the model; that is, the greatervention comprised thrombolysis, PTA, or surgery in
any arterial section. Hypertension, diabetes mellitus sensitivity and specificity of the model for predicting
graft occlusion. Information content of the models isand hyperlipidaemia were present if a patient was
treated for it. In 97% of the patients vein grafts con- quantified by calculation of the areas under the curve.
An area under the curve of 0.5 indicates no prognosticsisted of the greater saphenous vein (63% reversed
and 35% in situ), and in 3% of all patients other venous value at all, whereas an area under the curve of 1
means a sensitivity and specificity of the model ofgrafts were used. Inherent to the design of the trial,
half of the patients were allocated to postoperative 100%.
oral anticoagulant treatment (INR 3.0–4.5), whereas
the other half of the patients received aspirin (80 mg
daily). Results
The mean length of follow-up was 21 months (range,
0–45 months) during which 630 grafts occluded
Follow-up (23.8%); 469 (22.1%) in the femoropopliteal group (n=
2119) and 161 (30.3%) in the femorocrural group (n=All patients were evaluated 3 and 6 months post- 531).operatively and every 6 months thereafter. Graft pat-
ency was assessed by clinical examination and by
Doppler or duplex scanning and arteriography when
Univariate analysisindicated.
Higher ankle blood pressures were associated with a
lower risk for graft occlusion, whereas female gender,
critical ischaemia, femorocrural bypass and use ofData analysis
non-venous graft material were related to a higher
probability of graft occlusion (Table 1).The object of analysis was to find the combination of
baseline characteristics that most accurately predicted In the subgroup analysis of patients with femoro-
popliteal bypasses, poor (one or no patent) run-offthe occurrence of graft occlusion. After analysis of all
patients, subgroup analysis of patients with femoro- artery appeared to be a risk factor as well, whereas
ankle blood pressure just failed to reach statisticalpopliteal and femorocrural bypasses was performed.
In the univariate analysis we calculated the hazard significance. Infragenicular distal anastomosis was not
associated with graft occlusion. Analysis of the patientsratios with corresponding 95% confidence intervals
(CI) of the considered risk factors by means of the Cox with femorocrural bypasses revealed use of non-ven-
ous graft material as the only risk factor for occlusion.proportional hazards model.9
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Table 1. Results of univariate analysis of risk factors for infrainguinal graft occlusion.
All patients, n=2650 Femoropopliteal grafts, n=2119 Femorocrural grafts, n=531
% with HR 95% CI % with HR 95% CI % with HR 95% CI
variable or variable or variable or
Variable mean±s.d. mean±s.d. mean±s.d.
Demographic factors
Female gender 36 1.21 1.03–1.42 35 1.31 1.09–1.57 38 0.95 0.69–1.31
Age 69±10 0.996 0.989–1.005 68±9.8 0.994 0.985–1.003 72±10 0.994 0.980–1.009
Medical history
Angina pectoris 17 0.94 0.76–1.17 16 0.90 0.70–1.16 19 1.02 0.69–1.52
Myocardial infarction 18 0.99 0.80–1.22 17 0.96 0.75–1.23 18 1.04 0.70–1.54
TIA/stroke 12 0.94 0.72–1.21 11 0.93 0.68–1.27 15 0.86 0.54–1.38
Vascular intervention∗ 45 1.03 0.88–1.21 45 1.03 0.86–1.24 45 1.05 0.77–1.43
Vascular risk factors
Current smoking 54 1.03 0.88–1.20 57 1.10 0.91–1.32 43 1.01 0.74–1.37
Hypertension‡ 39 0.85 0.72–1.00 39 0.82 0.68–1.00 40 0.94 0.68–1.29
Diabetes mellitus‡ 26 1.12 0.94–1.33 24 1.10 0.89–1.36 37 0.98 0.71–1.36
Hyperlipidaemia‡ 16 0.81 0.65–1.01 17 0.81 0.62–1.04 13 0.90 0.56–1.44
Brachial blood pressure# 159±31 0.998 0.995–1.001 159±31 0.998 0.995–1.001 158±32 0.999 0.993–1.005
Ankle blood pressure# 85±38 0.997 0.995–0.999 88±37 0.998 0.995–1.000 70±42 0.998 0.993–1.003
Ankle–brachial index# 0.55±0.34 0.78 0.58–1.05 0.57±0.33 0.84 0.61–1.16 0.45±0.32 0.82 0.43–1.58
Critical ischaemia 49 1.35 1.15–1.58 40 1.21 1.01–1.45 82 1.29 0.83–1.98
Run-off ≤1 artery — — — 23 1.30 1.06–1.60 — — —
Below-knee anastomosis — — — 42 0.97 0.80–1.16 — — —
Femorocrural bypass 20 1.54 1.29–1.85 — — — — — —
Non-venous graft 42 2.10 1.79–2.46 46 2.23 1.85–2.69 24 2.97 2.16–4.08
Aspirin vs. anticoagulants 50 1.05 0.90–1.23 50 1.04 0.86–1.24 52 1.05 0.77–1.43
∗Any intervention in any arterial section.
‡ Variable is present when the patient was treated for it.
# Blood pressures were available in 2160 of all patients, in 1785 of the patients with femoropopliteal grafts and in 375 patients with
femorocrural grafts.
s.d.=standard deviation. HR=hazard ratio. CI=confidence interval.
Table 2. Results of multivariate analysis of risk factors for infrainguinal graft occlusion (all
bypasses, n=2650).
Office only model Complete model
Variable HR 95% CI HR 95% CI
Female gender 1.22 1.02–1.46
Critical ischaemia 1.29 1.08–1.53 1.29 1.07–1.56
Femorocrural bypass 1.76 1.40–2.23
Non-venous graft 2.45 2.03–2.95
“Office only” model: history and clinical findings only. Complete model: history, clinical,
radiological and surgical findings. HR=hazard ratio. CI=confidence interval.
Multivariate analysis femoropopliteal bypasses are shown in Table 3. In the
‘‘office only’’ model only female gender appeared to
The ‘‘office only’’ model, developed with data available be associated independently with graft occlusion. The
‘‘complete’’ model indicated female gender, criticalfrom patient history and clinical examination, revealed
female gender and critical ischaemia as independent ischaemia, poor run-off and use of non-venous graft
material as independent predictors of graft occlusion.prognostic factors for graft occlusion (Table 2). In the
‘‘complete’’ model, in which data from radiological
and operative findings were added, femorocrural by- Additional analysis
pass and use of non-venous graft material proved to
be additional independent risk factors. Because the use of non-venous graft material appeared
to be the strongest independent risk factor of graftThe results of subgroup analysis of the patients with
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Table 3. Results of multivariate analysis of risk factors for femoropopliteal graft occlusion
(n=2119).
Office only model Complete model
Variable HR 95% CI HR 95% CI
Female gender 1.31 1.09–1.57 1.21 1.01–1.45
Critical ischaemia 1.22 1.01–1.48
Run-off Ζ1 vessel 1.26 1.02–1.56
Non-venous graft 2.29 1.89–2.77
“Office only” model: history and clinical findings only. Complete model: history, clinical,
radiological and surgical findings. HR=hazard ratio. CI=confidence interval.
occlusion, notably in femoropopliteal bypass grafts, us the opportunity to calculate precise estimates of
an additional analysis of patients with supragenicular the prognostic importance of vascular risk factors for
femoropopliteal bypasses (n=1222) was performed. infrainguinal bypass graft occlusion. Only a few in-
Univariate analysis demonstrated that increasing bra- dependent risk factors were identified. The in-
chial blood pressure, treated hypertension and hyper- formation content of the ‘‘office only’’ model,
lipidaemia were associated with a lower risk for graft containing data available from preoperative interview
occlusion, whereas critical ischaemia, poor run-off and and physical examination, was extremely poor. Add-
use of non-venous graft material were related to a ing radiological and surgical data resulted in a more
higher probability of graft occlusion. Multivariate ana- informative, but far from perfect, ‘‘complete’’ model.
lysis using the ‘‘office only’’ model indicated increasing This model identified critical ischaemia, femorocrural
brachial blood pressure as the only independent factor bypass and use of non-venous graft material in all
associated with a lower risk of graft occlusion (hazard patients, supplemented by female gender and poor
ratio 0.994; 95% CI 0.990–0.999). The ‘‘complete’’ model run-off in patients with femoropopliteal bypasses, as
revealed brachial blood pressure (hazard ratio 0.994; independent risk factors for occlusion. Other variables
95% CI 0.990–0.999), hyperlipidaemia (hazard ratio which are generally considered to be vascular risk
0.66; 95% CI 0.45–0.97), poor run-off (hazard ratio factors did not predict graft occlusion.
1.45; 95% CI 1.06–1.99) and non-venous graft material, The higher risk for graft occlusion in women was
which was used in 64% of the patients (hazard ratio also seen in a recent review of outcome of infrainguinal
2.44; 95% CI 1.18–3.34), as independent prognostic bypass surgery.10 Although men are more prone to
factors for graft occlusion. atherosclerotic disease than women, atherosclerosis
appears to be more advanced by the time women need
surgical treatment. In the present study, women were,
on average, 4 years older than men, but had lessInformation content
vascular interventions in the past (36% versus 51%,
p<0.001). Women more often had surgery because ofThe ROC curve (Fig. 1a) of the “office only” model
critical ischaemia (56% versus 45%, p<0.001), and infor all patients is only slightly elevated above the
dotted line of no prognostic value. The corresponding 45% of the women a non-venous graft was inserted
area under the curve is 0.55 (95% CI 0.53–0.57). The compared with 40% of the men (p=0.01). The latter
“complete” model contained significantly more in- difference may be due to a smaller proportion of
formation, the area under the curve (Fig. 1b) is 0.64 graftable greater saphenous veins in women, caused
(95% CI 0.62–0.66). In patients with femoropopliteal by, for example, varicose or small diameter. However,
bypass grafts (Figs 1c and 1d) the information content female gender is a risk factor for femoropopliteal graft
of the “office only” model is also poor (area under the occlusion independent of these factors.
curve 0.54; 95% CI 0.48–0.60), whereas the “complete” Critical ischaemia, femorocrural or femoropedal by-
model has a significantly higher predictive value (area pass grafting and, in patients with femoropopliteal
under the curve 0.64; 95% CI 0.62–0.66). bypasses, poor arterial run-off are generally assumed
to be risk factors for graft occlusion. These factors,
however, if present, or not avoidable. The most pro-
nounced independent risk factor for occlusion, use ofDiscussion
non-venous graft material is, in the event that a suitable
vein is present, susceptible to intervention. Based onThis prospective study in a large group of patients
who were included in a multicentre clinical trial gave several studies,11–13 most of us agree on the preferred
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Fig. 1. ROC curves for all patients: the “office only” model (a) and the “complete” model (b), and ROC curves for patients with
femoropopliteal bypass grafts: the “office only” model (c) and the “complete” model (d). The dotted line represents no prognostic value
at all.
use of the greater saphenous vein for below-knee patients with a polytetrafluoroethylene (PTFE) supra-
genicular graft, multivariate analysis did not dem-bypasses. However, whether or not we should pre-
ferably use the autogenous vein for above-knee bypass onstrate any effect of the graft materials on patency.5
The study did show, however, that only 7% of thegrafting still remains a matter of debate. Advocates of
use of prosthetic materials in this position found upon patients needed a secondary below-knee bypass in the
same limb during 4 years’ follow-up. So far, we dosimilar patency rates of supragenicular prosthetic
grafts and vein grafts. Advantages of use of prosthetic not know how many patients in our study, particularly
those with supragenicular prosthetic grafts, havegrafts are preservation of the greater saphenous vein
for later use and shorter operation time. In a pro- needed their saphenous vein for revascularisations
carried out for progression of atherosclerotic disease.spective study in 310 patients who received above-
knee autologous saphenous vein bypass and 132 In the present study, 64% of the above-knee bypasses
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Elsman, R.W.H. van Reedt Dortland, J.J.F. Steijling,Haarlem (10; H.L.F. Brom, A. Jansen, A.R. Koomen);
Ziekenhuis St. Jansdal Harderwijk (22; W.L. Akkers- Th.J.M.V. van Vroonhoven); Ziekenhuis Overvecht
Utrecht (54; B.C.V.M. Disselhoff); St. Joseph Ziekenhuisdijk, A.C. van der Ham, A.K. Marck, M. Scheuer);
Atrium Medisch Centrum Heerlen (20; E.C.M. Bollen, Veghel (36; C.J. Broers, H.A.P.A. de Geus); St. Joseph
Ziekenhuis Veldhoven (24; M.H.M. Bender, J.A. Char-R.J.Th.J. Welten); Streekziekenhuis Midden Twente
Hengelo (24; P. van der Sar); Bosch Medicentrum bon, Th.J. van Straaten); St. Maartens Gasthuis Venlo
(8; P.F. Verhagen); Holy Ziekenhuis Vlaardingen (57;locatie Groot Ziekengasthuis ’s-Hertogenbosch (22; J.
Wever, F.G.J. Willekens, R.J. de Wit); Bosch Medi- E.R. Snijder); Streekziekenhuis Koningin Beatrix
Winterswijk (2; A.A. Vafi); Hofpoort Ziekenhuis Woer-centrum locatie Willem-Alexander Ziekenhuis ’s-Her-
togenbosch (60; R.M.M. van Loenhout, T.J.M.J. den (26; E. Bakker, W. van Eesteren); Kennemer Gast-
huis locatie Zeeweg IJmuiden (3; J.J. Petit); StichtingSchiphorst, J.C. Wissing); Carolus-Liduina Ziekenhuis
’s-Hertogenbosch (22; I.P.T. van Bebber, S. Bouwer, E.J. Ziekenhuis De Heel Zaandam (2; R.A. Cohen, R.P.
Strating); Streekziekenhuis Zevenaar (33; R.F. de Haan,Carol, J.H. Duppen, F.T.T. Liem); Ziekenhuis Hil-
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